X‑Chem Strengthens Executive Leadership With New Strategic Appointments In Finance And Human Resources

X-Chem, a global company specializing in data-driven drug discovery and DNA-encoded library (DEL) technology, has announced two key additions to its leadership team to support its continued growth and expanding discovery partnerships. Stephen Fair has been appointed Chief Financial Officer, and Maureen Hart has joined as Senior Vice President of Human Resources. Stephen Fair brings close to 20 years of experience in strategic finance and operations within the biotech and pharmaceutical sectors. 

Before joining X-Chem, he was Senior Vice President of Finance at Abata Therapeutics, where he led financial planning and operations. He has also held senior finance roles at FogPharma, Agios Pharmaceuticals, and Merrimack Pharmaceuticals. Stephen holds a B.A. in Economics from Yale University and an MBA from Stanford University. Maureen Hart joins X-Chem with a strong background in human resources leadership, having worked across the pharmaceutical, biotech, and healthcare industries. She has supported global teams in North America, Europe, and Asia, with a focus on building scalable HR systems and fostering high-performing cultures. 

Karen Lackey, CEO of X-Chem, stated, “Stephen and Maureen bring complementary strengths that will help propel X-Chem into its next phase. Stephen’s strategic financial leadership and Maureen’s track record in building high-performing organizations are critical as we deepen partnerships and deliver on our mission to transform drug discovery.”

Most recently, she led the U.S. HR team at WuXi Biologics, helping the company expand from 50 to 500 employees while managing talent strategy, employee engagement, and organizational development. She has also held senior HR roles at Shire and athenahealth. These appointments reflect X-Chem’s commitment to strengthening its leadership to support operational scale-up and deepen its presence in collaborative drug discovery.